Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Significance: Pyoderma gangrenosum (PG) is a rare debilitating autoinflammatory ulcerative skin disease. No gold standard has been established for the treatment of PG. The role of surgical interventions and negative pressure wound therapy (NPWT) was discussed controversially until recently as these...

Descripción completa

Detalles Bibliográficos
Publicado en:Advances in Wound Care (2162-1918) Vol. 9; no. 7; pp. 405 - 426
Autores principales: Eisendle, Klaus, Thuile, Tobias, Deluca, Jenny, Pichler, Maria
Formato: pictorial research systematic review tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Jul2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143696228&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 143696228
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21621918
        EGZ0
      jtl: Advances in Wound Care (2162-1918)
      issn: 21621918
      maglogo: N
    pubinfo:
      dt: Jul2020
      vid: 9
      iid: 7
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        143696228
        143696228
        143696228
        10.1089/wound.2020.1160
        143696228
      ppf: 405
      ppct: 21
      formats:
      tig:
        atl: Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.
      aug:
        au:
          Eisendle, Klaus
          Thuile, Tobias
          Deluca, Jenny
          Pichler, Maria
        affil: Department of Dermatology, Venereology and Allergology, Academic Teaching Department of Medical University Innsbruck, Central Teaching Hospital Bolzano/Bozen, Bolzano/Bozen, Italy.
      sug:
        subj:
          Pyoderma Gangrenosum Surgery
          Surgery, Reconstructive Methods
          Negative Pressure Wound Therapy Methods
          Skin Transplantation Methods
          Xenografts
          Immunosuppression Methods
          Combined Modality Therapy
          Treatment Outcomes
          Human
          Recurrence Prevention and Control
          Interleukins Therapeutic Use
          Antibodies, Monoclonal Therapeutic Use
      ab: Significance: Pyoderma gangrenosum (PG) is a rare debilitating autoinflammatory ulcerative skin disease. No gold standard has been established for the treatment of PG. The role of surgical interventions and negative pressure wound therapy (NPWT) was discussed controversially until recently as these procedures might pose a trigger to further aggravate the condition. Recent Advances: Recent advances confirm the paradigm change that a surgical approach of PG with split thickness skin grafting (STSG) secured by NPWT is a safe and valuable treatment if performed under adequate immunosuppression. We elaborate this on the hand of a broad literature search retrieving 101 relevant articles describing 138 patients complemented with our personal experience on 23 patients, including 2 patients treated with a porcine xenodressing. Critical Issues: A wide range of surgical approaches have been reported, including xenografts. Treatment was finally successful in 86%, including the xenotransplant cases. Ten percent improved and failures were mainly reported without immunosuppression. Despite halting the inflammatory process, NPWT alone, without skin grafting, does not much accelerate healing time. The best surgical approach appears to be STSG fixed with NPWT as this leads to higher skin graft take. There remains the problem of the chronic nature of PG and the recurrence after tapering of immunosuppression or trauma; therefore, a sustained immunosuppressive treatment is suggested. Future Directions: While surgical treatment is supported by the published data, the exact immunosuppression is still evolving. Due to deeper insights into pathogenesis and growing clinical reports, a broader utilization of biologic treatments and a shift from tumor necrosis factor (TNF)-alpha to interleukin (IL)-12/23 or IL-23 antibodies alone are predictable, as IL-12/23 antibodies show good clinical responses with fewer side effects. The positive results with porcine xenodressings might be due to immunological effects of the xenomaterial; they appear promising, but are preliminary and should be confirmed in a larger patient collective.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N